Loading stock data…
Takeda Pharmaceutical Company L (TAK)
$17.24+0.42 (+2.50%)
Market ClosedLast close Jul 24
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Takeda Pharmaceutical Company Limited in the Healthcare sector is trading at $17.24 with a market capitalization of $50.5B. Wall Street consensus targets $20.83 (3 analysts), implying a +20.8% move over the next 12 months. The stock is currently 9% below its 52-week high of $18.90, remaining 6.5% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +20.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.09T↓ | $1.19T↑ | $1.11T↑ | $1.11T↑ | $1.05T |
| Gross Profit | $688.84B↓ | $790.55B↑ | $732.74B↑ | $722.01B↑ | $671.32B |
| Operating Income | $42.07B↓ | $168.82B↑ | $69.00B↓ | $184.56B↑ | $68.54B |
| Net Income | -$368.47B↓ | $103.64B↑ | -$11.80B↓ | $124.24B↑ | -$103.16B |
Peer Comparison
JNJUNHPFE
Fundamentals
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therap...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$50.49B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2.05%
Volume
Today's trading volume
3.27M
Recent News
Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading
Asian equities traded in the US as American depositary receipts were tracking lower Friday morning,
Will Recent Setbacks Impact Growth Prospects of DNLI Stock?
Denali Therapeutics gains FDA approval for Avlayah, but pipeline setbacks and partner exits raise fresh questions as key clinical programs continue.
Takeda and Indonesia partner on plasma-derived therapies
Takeda plans to invest up to $30m to begin establishing an ecosystem for PDMPs and a plasma donation pilot.
Moderna, Takeda and Capricor on the verge of notching big drug approvals
Two of the companies are taking a second-go at FDA approval this summer, while another hopes to cement its leader-status in the battle to bring a new sleep treatment to market.
Is Recursion Pharmaceuticals (RXRX) The Best Penny Stocks According to Billioanires?
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Best Penny Stocks to Invest In According to Billionaires. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotechnology company that is building an AI-native discovery platform to industrialize drug discovery. Although still in the clinical stage, the company generates much of its revenue from key partnerships and collaborations with […]